Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01717586 · ClinicalTrials.gov registry record · Phase 1

Pravastatin for Prevention of Preeclampsia

A Phase 1 study of Preeclampsia, sponsored by The University of Texas Medical Branch, Galveston.

Completed
Registry status
Phase 1
Development phase
48
Enrollment target
3
Study locations

NCT01717586 is a Phase 1 study of Preeclampsia that has completed, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 48 participants, below the 1,281-participant average among 39 other Preeclampsia trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01717586, a Phase 1 study of Preeclampsia, has completed, sponsored by The University of Texas Medical Branch, Galveston.

COMPLETED
Registry status
Phase 1
Development phase
48 participants
Enrollment target
3
Study locations

Study Summary

The primary purpose of this pilot study is to determine the pharmacokinetic (PK) parameters and collect preliminary safety data for pravastatin when used as a prophylactic daily treatment in pregnant women at high risk of preeclampsia.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Pravastatin

Study Locations (3)

Illinois

  • Northwestern University - Chicago

Pennsylvania

  • University of Pittsburgh - Pittsburgh

Texas

  • University of Texas Medical Branch - Galveston

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2012-08
Est. Completion 2024-02-12
Phase Phase 1

What the Registry Record Tells You About NCT01717586

The ClinicalTrials.gov registry entry for NCT01717586 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,281-participant average among 39 other Preeclampsia trials with a reported enrollment target (96% lower). The listed sponsor is The University of Texas Medical Branch, Galveston, which has 203 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Preeclampsia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01717586 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Illinois, Pennsylvania, Texas.

Frequently Asked Questions

What is clinical trial NCT01717586 about?

NCT01717586 is a clinical study titled "Pravastatin for Prevention of Preeclampsia". The primary purpose of this pilot study is to determine the pharmacokinetic (PK) parameters and collect preliminary safety data for pravastatin when used as a prophylactic daily treatment in pregnant women at high risk of preeclampsia.

What is the current status of trial NCT01717586?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2012-08. Estimated completion is 2024-02-12.

What conditions does trial NCT01717586 study?

This clinical trial studies the following conditions: Preeclampsia.

What interventions are being tested in trial NCT01717586?

The interventions under investigation include: Placebo (DRUG), Pravastatin (DRUG).

Who is sponsoring clinical trial NCT01717586?

This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01717586 being conducted?

This trial has 3 study locations across Illinois, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Preeclampsia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.